Thr53
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr53  -  MAFA (human)

Site Information
PPGsLSStPLStPCS   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 1320402

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 1 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , phosphopeptide mapping ( 1 ) , western blotting ( 1 )
Disease tissue studied:
pancreatic cancer ( 1 ) , pancreatic carcinoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
GSK3A (human) ( 1 ) , GSK3B (human) ( 1 )
Kinases, in vitro:
GSK3B (human) ( 1 )
Treatments:
1-azakenpaullone ( 1 ) , lithium ( 1 ) , seliciclib ( 1 ) , U0126 ( 1 )

Downstream Regulation
Effects of modification on MAFA:
molecular association, regulation ( 1 ) , protein degradation ( 1 ) , ubiquitination ( 1 )
Effects of modification on biological processes:
carcinogenesis, induced ( 1 ) , transcription, induced ( 1 )
Induce interaction with:
PCAF (human) ( 1 )

References 

1

Rocques N, et al. (2007) GSK-3-mediated phosphorylation enhances Maf-transforming activity. Mol Cell 28, 584-97
18042454   Curated Info